Genzyme reorganization?
Executive Summary
Genzyme CEO Henri Termeer was asked several times during April 16 conference call about the company's capital structure in light of recent concerns about tracking stocks and corporate accounting. "We are always looking at the capital structure of the company. We are doing that now and will be looking at doing that in the future," Termeer says. Pressed for further comment, Termeer says, "this is an earnings call, not a structure call"...
You may also be interested in...
Genzyme ends tracking-stock structure
Genzyme will exchange shares of Genzyme Biosurgery stock and Genzyme Molecular Oncology stock for shares of Genzyme General stock on June 30. "We do not expect to make any major changes within our business or research programs at this time," CEO Henri Termeer says. Termeer was asked about the company's capital structure in light of concerns about tracking stocks and corporate accounting during an April 16 earnings call (1"The Pink Sheet" April 28, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.